We have located links that may give you full text access.
Hemophagocytic lymphohistiocytosis in Egyptian children: diagnosis, treatment challenges and outcome.
Expert Review of Hematology 2024 April 11
BACKGROUND: Hemophagocyticlymphohistiocytosis (HLH) is a spectrum of immune activation which could be genetically determined, or secondaryto an underlying illness. Our aim was to present the clinico-genetic aspects ofHLH among Egyptian children and to evaluate the patterns of reactivation and outcomewith illustrations of overlap manifestations.
RESEARCH DESIGNAND METHODS: We retrospectively collected the data of 55patients with HLH, registered at Ain Shams University Children's Hospital,Cairo, Egypt.
RESULTS: Median age at diagnosis was 19 months (range 2-180), 33 patients (60%)fulfilled the diagnostic HLH criteria at presentation. Fourteen (25.45%) patients had secondary HLH, 15 (27.27%) patients had geneticallydocumented familial HLH (11 had variants in UNC13D gene and one in PRF1 gene), 3 had Griscelli and Chediak-Higashi syndrome. Sixteen patients (29.1%) had reactivations, 8(50%) of themhad molecularly confirmed HLH. Wereport the death of 40 patients, the median duration from the diagnosis todeath of 5 months mostly due to disease activity.
CONCLUSIONS: This study confirms that the nonspecific signsand symptoms of HLH arechallenging. Genetic testing, though expensive and sophisticated, is integralfor the diagnosis. The difficulty in finding non-related donors for stem celltransplantation and the early reactivations are the causes of the inferioroutcome.
RESEARCH DESIGNAND METHODS: We retrospectively collected the data of 55patients with HLH, registered at Ain Shams University Children's Hospital,Cairo, Egypt.
RESULTS: Median age at diagnosis was 19 months (range 2-180), 33 patients (60%)fulfilled the diagnostic HLH criteria at presentation. Fourteen (25.45%) patients had secondary HLH, 15 (27.27%) patients had geneticallydocumented familial HLH (11 had variants in UNC13D gene and one in PRF1 gene), 3 had Griscelli and Chediak-Higashi syndrome. Sixteen patients (29.1%) had reactivations, 8(50%) of themhad molecularly confirmed HLH. Wereport the death of 40 patients, the median duration from the diagnosis todeath of 5 months mostly due to disease activity.
CONCLUSIONS: This study confirms that the nonspecific signsand symptoms of HLH arechallenging. Genetic testing, though expensive and sophisticated, is integralfor the diagnosis. The difficulty in finding non-related donors for stem celltransplantation and the early reactivations are the causes of the inferioroutcome.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app